Anidulafungin

Therapeutic

For use in the treatment of the following fungal infections: Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis), Aspergillus infections, and esophageal candidiasis. Also considered an alternative treatment for oropharyngeal canaidiasis.

Structural features

SMILES

CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)O)O

Sequence

XXTXXTX

Molar mass

1140.254 g/mol

Constitutional members:

7

Natural amino acids

2

D-Amino acids

0

N-terminus

pentoxyphenyl phenyl benzoyl

C-terminus

cycle

Cyclic

yes

Members/cycle

6

Bond to form cycle

head-to-side chain

Lipidation

no

Glycosylation

no

Route of administration

IV

Terminal half-life

40-50 hours

Protein binding

0.84

Absorption and Bioavailability

100% (IV); 2-7% (ORAL)

References